Par Pharmaceutical, an operating company of Endo International plc (NASDAQ: ENDP), has started shipping an authorised generic version of Allergan's Carafate (sucralfate) oral suspension 1gm/10mL, it was reported on Monday.

Domenic Ciarico, executive vice president & chief commercial officer, Sterile & Generics at Endo, said, 'Par is proud to partner with Allergan to bring the authorised generic of Carafate to patients. We are pleased to add this product to our portfolio and continue Par's tradition of being a reliable, quality supplier.'

Carafate is a registered trademark of Aptalis Pharma Canada ULC, an affiliate of Allergan Inc. IQVIA data states that US market annual sales for sucralfate oral suspension for the 12 months ended 30 November 2019, was estimated at approximately USD285m.